Alvotech Inks Long-Term Agreement With A Strategic Partner To Further Enhance Access To Adalimumab-ryvk In US Market
Alvotech Inks Long-Term Agreement With A Strategic Partner To Further Enhance Access To Adalimumab-ryvk In US Market
Alvotech與戰略合作伙伴簽署長期協議,以進一步增加在美國市場獲得Adalimumab-RYVK的機會
"This new partnership agreement supports our financial guidance and reflects Alvotech's strong commitment to increasing patient access to more affordable healthcare," said Robert Wessman, Chairman and CEO of Alvotech.
Alvotech董事長兼首席執行官羅伯特·韋斯曼表示:“這項新的合作協議支持了我們的財務指導,也反映了Alvotech對增加患者獲得更實惠的醫療保健機會的堅定承諾。”
The current multi-product commercialization partnership between Teva Pharmaceuticals and Alvotech remains unchanged and Teva will continue to commercialize adalimumab-ryvk under the SIMLANDI brand in the U.S.
梯瓦製藥與Alvotech之間目前的多產品商業化合作夥伴關係保持不變,梯瓦將繼續在美國以SIMLANDI品牌將adalimumab-ryvk商業化。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。